Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type | NCT00041678 | Trialant
CompletedInterventionalPhase 3Updated Nov 11, 2013
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type
ClinicalTrials.gov ID
NCT00041678
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Last Update Posted
Nov 11, 2013Estimated
Start Date
Jan 2000
Primary Completion Date
Mar 2003Actual
Completion Date
Mar 2003Actual
Brief Summary
The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
Alzheimer Disease
aripiprazole
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Institutionalized patients with Alzheimer's Disease
Primary Purpose
Treatment
No central contacts
There are no central contacts for this study.
Local Institution
Rosemead, California, United States
Local Institution
Miami, Florida, United States
Local Institution
Nashville, Tennessee, United States
Local Institution
Bennington, Vermont, United States
Local Institution
Burlington, Vermont, United States
Local Institution
Milwaukee, Wisconsin, United States
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY